Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.54 |
| ▸ | MTOR | P42345 | 5/20 | 0.43 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3755252 | 1.00 | NOS1 (0.54) | NOS1MTORJAK2JAK3SCN9A | |
| SCHEMBL3762310 | 0.90 | NOS1 (0.56) | NOS1MTORJAK2JAK3PRKDC | |
| SCHEMBL3762311 | 0.90 | NOS1 (0.56) | NOS1MTORJAK2JAK3PRKDC | |
| SCHEMBL3760610 | 0.83 | NOS1 (0.61) | NOS1MTORJAK2JAK3ATR | |
| SCHEMBL3760595 | 0.83 | NOS1 (0.61) | NOS1MTORJAK2JAK3ATR | |
| SCHEMBL3765184 | 0.82 | NOS1 (0.64) | NOS1MTORJAK2JAK3ATR | |
| SCHEMBL4841936 | 0.82 | NOS1 (0.37) | NOS1MTORJAK2SCN9A | |
| SCHEMBL3765421 | 0.82 | NOS1 (0.63) | NOS1MTORJAK2JAK3ATR | |
| SCHEMBL3765436 | 0.82 | NOS1 (0.63) | NOS1MTORJAK2JAK3ATR | |
| SCHEMBL3770209 | 0.82 | NOS1 (0.71) | NOS1MTORATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | GILEAD SCIENCES, INC. (US) | 2018-12-04 | — | — | US | claimed |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-12-02 | — | — | US | claimed |
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-05-23 | — | — | US | disclosed |
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | GILEAD SCIENCES, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HCCS, DPYD, HAVCR2 | NOS1 2154/4885MTOR 3424/4885JAK2 3100/4885 |
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | HCCS, DPYD, HAVCR2 | NOS1 2154/4885MTOR 3424/4885JAK2 3100/4885 |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HCCS, DPYD, HAVCR2 | NOS1 2154/4885MTOR 3424/4885JAK2 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.